Saturday 17 October 2026 Export BGM’s income statement to Excel — free account

BGM Group Ltd.

BGM Healthcare Drug Manufacturers Specialty & Generic

BGM Group Ltd.’s revenue for fiscal 2025 (year ended September 2025) was $37.9 million, up 51.1% from fiscal 2024.

8.65 0.06 +0.70%

Follow BGM

Alert me

Market cap: $114.7M
P/E: 144×
Fwd P/E: 44.9×
Dividend yield: —
F-score: 3/9
Altman Z: 498.01
Beneish M: −0.93
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 89.73%

Capital & Financial Ratios $m

Market Cap 114.71

Revenue 121.18

Net Income (24.77)

Free Cash Flow (8.99)

Net Debt (10.46)

Current Ratio 1.25

Debt/Equity 0.00

P/E ratio 144.17

Fwd P/E 44.90

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth (822.60%)

Next Y EPS Growth —

Next Y revenue growth 13.66%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 11.03%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	0.05	0.05
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	22	18	11	12
Receivables	2	2	4	4
Inventory	5	5	20	19
Other	1	2	13	8
	35	30	52	46

	2023	2024	2025	Q'26
Payables	4	4	7	6
ST’ Debt	0	—	—	1
Other	1	0	3	4
	7	9	42	37

Compound Annual Growth %

	10y	5y	3y
Sales	—	(5.39%)	(16.38%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	68.51%	92.47%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	38
’24	—	—	—	—	25
’23	—	—	—	—	46
’22	—	—	—	—	65
’21	—	—	—	—	57
’20	—	—	—	—	50

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(2)
’24	—	—	—	—	1
’23	—	—	—	—	0
’22	—	—	—	—	13
’21	—	—	—	—	0
’20	—	—	—	—	5

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	2	—	—	—	—
’25	(4)	—	(4)	—	(5)
’24	2	—	(2)	—	(3)
’23	(1)	—	(2)	—	(3)
’22	2	—	9	—	9
’21	9	—	(3)	—	(3)
’20	5	—	5	—	5

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(0.18)
’24	—	—	—	—	(0.20)
’23	—	—	—	—	(1.10)
’22	—	—	—	—	0.15
’21	—	—	—	—	0.45
’20	—	—	—	—	0.85

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	390.00	108.00	55.50	53.25	106.50	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	3,300.00	414.30	321.00	350.10	515.10
People
People	Employees	—	—	—	288	292	283	344	298	323	335
	Revenue/emp, $m	—	0.00	0.00	0.16	0.17	0.20	0.19	0.16	0.08	0.11
Income, $m
Income, $m	Revenue	—	23	50	46	50	57	65	46	25	38
	Gross margin, %	—	15.01	16.15	21.00	15.07	9.87	9.60	3.77	16.39	16.64
	EBT	—	2	6	7	6	3	2	(8)	(2)	(20)
	EBT margin, %	—	8.25	12.20	15.06	11.60	5.89	2.41	(17.01)	(8.52)	(52.58)
	Net income	—	0	5	6	5	3	1	(8)	(2)	(20)
	Depreciation	—	1	1	1	1	1	1	1	1	1
Per share, $
Per share, $	Revenue	—	0.63	8.39	7.68	8.34	8.38	9.07	6.43	3.47	0.33
	Earnings	—	0.04	0.87	0.98	0.85	0.45	0.15	(1.10)	(0.20)	(0.18)
	Cash flow	—	0.08	0.74	(0.10)	0.85	0.05	1.77	0.04	0.08	(0.02)
	Capex	—	0.00	(0.19)	(0.10)	(0.08)	(0.51)	(0.46)	(0.51)	(0.54)	(0.02)
	Free cash flow	—	0.08	0.55	(0.20)	0.77	(0.46)	1.31	(0.47)	(0.47)	(0.04)
	Book value	—	0.31	2.95	3.77	4.81	8.31	7.69	6.14	6.10	3.46
	Shares, m	—	36	6	6	6	7	7	7	7	113
Valuation, ×
Valuation, ×	P/E	—	21.28	21.28	21.28	21.28	1,487.50	1,487.50	1,967.50	3,995.00	5,120.00
	P/S	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/B	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	EV/Sales	—	0.00	0.00	0.00	0.00	0.00	(0.12)	(0.18)	(0.15)	(0.08)
	EV/FCF	—	(0.32)	(0.32)	(0.32)	(0.32)	(0.32)	(0.86)	(2.33)	6.15	1.02
Cash, $m
Cash, $m	Operating cash flow	—	3	4	(1)	5	0	13	0	1	(2)
	Capex	—	(2)	(1)	(1)	0	(3)	(3)	(4)	(4)	(2)
	Free cash flow	—	3	3	(1)	5	(3)	9	(3)	(3)	(5)
Balance, $m
Balance, $m	Working capital	—	4	8	13	19	22	21	28	21	10
	Total debt	—	7	4	5	7	8	0	0	—	—
	Net debt	—	1	(2)	0	(5)	(5)	(15)	(22)	(18)	(11)
	Shareholders’ equity	—	11	18	23	29	57	55	44	44	392
Returns, %
Returns, %	ROA	—	4.24	31.01	15.54	12.14	5.11	1.54	(13.44)	(2.77)	(8.19)
	ROIC	—	0.00	23.72	16.83	12.36	2.87	3.27	(7.28)	(1.36)	(2.06)
	ROE	—	10.65	35.70	26.42	19.67	7.37	1.93	(15.67)	(3.26)	(9.15)

Negative figures in brackets.

All 10 years →

Fiscal years to Sep 2025 · latest quarter Jan 0001

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
DERM Journey Medical Corporation	$144.7M	— (loss-making)	91.8×	+23.33% (above 0%: growing)	n/m	−84.08% (below 0%: shrinking)	66.81%	2.46%	Compare
ORGO Organogenesis	$142.8M	— (loss-making)	— (loss-making)	−56.68% (below 0%: shrinking)	n/m	+10.29% (above 0%: growing)	45.90%	(116.54%)	Compare
CRDL Cardiol Therapeutics Inc.	$138.8M	— (loss-making)	— (loss-making)	—	n/m	+10.61% (above 0%: growing)	0.00%	0.00%	Compare
OGI Organigram Global Inc.	$131.4M	2.0×	11.4×	+49.28% (above 0%: growing)	n/m	−192.32% (below 0%: shrinking)	39.16%	5.04%	Compare
BGM BGM Group Ltd.	$114.7M	144×	44.9×	−2.59% (below 0%: shrinking)	−85.71% (below 0%: shrinking)	+3.00% (above 0%: growing)	7.12%	0.00%
PROCF Sofgen Pharma S.A	$114.0M	0.1×	4.0×	+17.28% (above 0%: growing)	n/m	+231.11% (above 0%: growing)	56.09%	36.48%	Compare
CPIX Cumberland Pharmaceuticals Inc.	$113.0M	— (loss-making)	— (loss-making)	−56.28% (below 0%: shrinking)	n/m	−82.78% (below 0%: shrinking)	100.00%	(1,898.20%)	Compare
CLVR Clever Leaves Holdings Inc.	$96.5M	— (loss-making)	— (loss-making)	+5.36% (above 0%: growing)	n/m	+70.31% (above 0%: growing)	(7.46%)	(105.91%)	Compare
CTOR Citius Oncology, Inc.	$69.4M	— (loss-making)	—	—	n/m	0.00%	67.07%	(583.53%)	Compare
Median of peers	$122.7M	—	11.4×	+11.32%	—	+5.15%	51.00%	(52.95%)

All 86 Drug Manufacturers Specialty & Generic stocks →

BGM Group Ltd. (BGM) key facts

Strength: BGM Group Ltd.’s revenue for fiscal 2025 (year ended September 2025) was $37.9 million, up 51.1% from fiscal 2024.
BGM Group Ltd. (BGM) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, BGM traded at $8.65, a market capitalization of $114.7 million.
Return on equity was −9.15% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 498.01 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.